In the Claims

1. (Original) An 1-[(indol-3-yl)carbonyl]piperazine derivative having the general formula I



Formula I

wherein

R represents 1-4 substituents independently selected from H, (C_{1-4})alkyl (optionally substituted with halogen), (C_{1-4})alkyloxy (optionally substituted with halogen), halogen, OH, NH_2, CN and NO_2;

R_1 is (C_{5-8})cycloalkyl or (C_{5-8})cycloalkenyl;

R_2 is H, methyl or ethyl;

R_3, R_3', R_4' R_4', R_5, R_5' and R_6' are independently hydrogen or (C_{1-4})alkyl, optionally substituted with (C_{1-4})alkyloxy, halogen or OH;

R_6 is hydrogen or (C_{1-4})alkyl, optionally substituted with (C_{1-4})alkyloxy, halogen or OH; or

R_6 forms together with R_7 a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S;

R_7 forms together with R_6 a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O

and S; or

R_7 is H, (C_{1-4})alkyl or (C_{3-5})cycloalkyl, the alkyl groups being optionally substituted with OH, halogen or (C_{1-4})alkyloxy; or

a pharmaceutically acceptable salt thereof.

2. (Original) The 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, wherein R_2 is H and R_1 is (C_{5-6})cycloalkyl.

3. (Original) The 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 2, wherein R is (C_{1-4})alkyloxy or halogen.

4 (Original) The 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 3, wherein R represents a methoxy group at the 7-position of the indole ring.

5. (Original) The 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 4, wherein R_3, R_3', R_4', R_5, R_5' and R_6' are H; R_4, R_6 and R_7 are independently H or (C_{1-4})alkyl; or R_6 forms together with R_7 a 5- or 6-membered saturated heterocyclic ring and R_4 is H or (C_{1-4})alkyl.

6. (Currently Amended)) The 1-[(indol-3-yl)carbonyl]piperazine derivative according to ~~formula I of~~ claim 1, ~~which is selected from:~~ wherein the derivative is selected from the group consisting of

1-{[1-(cyclohexylmethyl)-7-methoxy-1*H*-indol-3-yl]carbonyl}-3,5-dimethyl-4-ethylpiperazine;

1-{[1-(cyclohexylmethyl)-7-methoxy-1*H*-indol-3-yl]carbonyl}-3,4,5-trimethylpiperazine;

(*S*)-1-{[1-(cyclohexylmethyl)-7-methoxy-1*H*-indol-3-yl]carbonyl}-3,4-dimethylpiperazine;

(*S*)-2-{[1-(cyclohexylmethyl)-7-methoxy-1*H*-indol-3-yl]carbonyl}-octahydro-2*H*-pyrido-[1, 2-a]pyrazine;

(*S*)-2-{[1-(cyclohexylmethyl)-7-methoxy-1*H*-indol-3-yl]carbonyl}-octahydro-2*H*-pyrrolo-[1, 2-a]pyrazine; and

(*S*)-2-{[1-(cyclopentylmethyl)1-7-methoxy-1*H*-indol-3-yl]carbonyl}-octahydro-2*H*-pyrido-[1, 2-a]pyrazine;

or a pharmaceutically acceptable salt thereof of each individual derivative.

7. (Canceled).

8. (Currently Amended) A pharmaceutical composition, comprising:

~~an~~ the 1-[(indol-3-yl)carbonyl]piperazine derivative of ~~any one of claims 1-6 together with~~ claim 1, and

a pharmaceutically acceptable carrier ~~therefor~~.

9. (Canceled).

10. (New) A method of inducing a agonist effect of a CB-1 receptor in a patient in need thereof, comprising:

administering an effective amount of the derivative according to claim 1 to induce an agonistic effect at the CB-1 receptor.

11. (New) A method of treating pain in a patient in need thereof, comprising:

administering an effective amount of the derivative according to claim 1.